Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-POC vanguard trial of colchicine for prevention of myocardial injury after CABG
ACTRN12617000203358Phase 4Not yet recruiting
- Sponsor
- Sydney Local Health District
- Start
- Mar 2017
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Myocardial injury, postpericardiotomy syndrome (PPS), Atrial fibrillation (AFib) and 2 more comparing Colchicine with Placebo (2 arms). Primary endpoint: Incidence of significant post-operative myocardial injury. Planned start Mar 2017; status: not yet recruiting.
02
Drugs
colchicine
03
Conditions
Myocardial injurypostpericardiotomy syndrome (PPS)Atrial fibrillation (AFib)pericardial effusionpleural effusion
Beyond the preview
Go deeper on ACTRN12617000203358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617000203358.